EAE MODEL IN BIOZZI ABH MICE
The Biozzi ABH mouse strain is susceptible to the development of secondary progressive EAE following a relapsing–remitting episode of approximately 3 months. EAE is induced in the ABH mouse by immunization with an emulsion of mouse spinal cord homogenate. The relapsing–remitting stages of EAE are strongly associated with auto-immune reaction, whereas the neurodegenerative component is associated with innate immunity. The Biozzi ABH mouse model of MS exhibits a reproducible relapsing-remitting disease course that slowly accumulates permanent neurological deficit and develops a post-relapsing progressive disease associated residual signs of disease such as spasticity and tremor. This model permits study of demyelination and neurodegeneration.
The studies using spinal cord antigen-induced disease model in Biozzi ABH mice can be completed within 100 days from disease induction. Mice are weighed and scored for clinical signs and severity of EAE daily.
EAE-MOG MODEL IN MICE
EAE is induced following the immunization of animals with a fragment of myelin protein. This initiates auto-immune reaction in the CNS and results in neurological motor symptoms. The symptoms of the disease manifest with progressive paralysis and the first signs appear 10 days following the initial immunization. Study completion within 40 days from disease induction.
REMITTING-RELAPSING EAE-MBP MODEL IN RATS
Remitting-Relapsing EAE is induced in rats by immunization with myelin basic protein (MBP). MBP-induced EAE is an acute monophasic paralytic central nervous system disease, which develops during a period of two weeks and is accompanied by severe CNS inflammation, with little or no demyelination.
The neuropathological lesions are found mainly in the spinal cord and brain stem. The affected animals develop hind limb paralysis. EAE lesions are characterized by edema, infiltration of mononuclear cells, and gliosis. The majority of rats display spontaneous recovery from paralysis within 7-10 days and remain resistant to the development of EAE with subsequent immunizations with MBP. The EAE-MPB model is beneficial for the studies in the field of acute CNS inflammation.
Studies using the EAE-MBP model in rats are completed within 30-40 days from disease induction. The treatment can be delivered either prophylactically, before clinical signs appearance or at the disease onset for evaluating therapeutic potential. Mice are weighed and scored for clinical signs and severity of EAE.
SYNGENEIC ANTIGEN INDUCED EAE IN DA RATS
DA rats develop severe, protracted and relapsing EAE after immunization with syngeneic spinal cord homogenate. The neurological deficits are accompanied by demyelinating inflammatory lesions in the spinal cord, with infiltrating T lymphocytes and perivascular deposition of immunoglobulins and complement. Study duration is between 20-60 days depending on individual experimental needs.
MULTIPLE SCLEROSIS (EAE)
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease of the central nervous system (CNS) affecting more than two million people worldwide. Multiple sclerosis causes gradual damage to the CNS resulting in sensory loss and compromised motor function. In the course of MS, an autoimmune response damages the myelin sheath. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of clinical and pathological phenotypes.
Experimental autoimmune encephalomyelitis (EAE) is an induced inflammatory autoimmune, demyelinating disease model in mouse or rat. EAE pathology closely resembles that of Multiple Sclerosis. EAE model recapitulates the progression and symptoms of the human neurological disease of MS.
SIA provides full services for the evaluation of test article efficacy in EAE Models of Human Multiple Sclerosis. Readout parameters are body weight, clinical score and histology. Additionally, samples can be isolated for further analyses including serum and tissue biomarker analyses, gene expression and more. Please refer to our in-vitro services section for more information on ex-vivo studies offered by SIA.